Objective: To investigate the effects of bone trauma therapy instrument combined with Guyuling capsule in the treatment of traumatic fractures and the effects on the levels of serum epidermal growth factor (EGF), transforming growth factor-1 (TGF-β1) and vascular endothelial growth factor (VEGF). Methods: The clinical data of 168 patients with traumatic fractures admitted to our hospital from January 2015 to December 2017 were retrospectively analyzed. According to different treatment methods, the patients were divided into the bone trauma treatment instrument group (54 cases), the bone Guyuling capsule group (52 cases) and the combined group (62 cases). All patients were treated with open internal fixation and routine anti-infection, detumescence, analgesic and other symptomatic treatment. The bone trauma therapeutic instrument group was given auxiliary treatment with bone trauma therapeutic instrument on the basis of conventional treatment, the bone healing capsule group was added with bone healing capsule treatment on the basis of conventional treatment, and the bone trauma therapeutic instrument and bone healing capsule combined treatment were given in the combined group at the same time. The clinical efficacy was compared and the serum levels of EGF, TGF-β1 and VEGF in the three groups were detected. Results: The detumescence time (8.37 ± 2.84 d vs. 10.76 ± 4.17 d, 11.64 ± 3.98 d, F=12.329) and the healing time (11.73 ± 3.44 week vs. 14.23 ± 4.62 week, 14.76 ± 5.17 week, F=7.835) of the combined group were significantly shorter than those of the bone trauma therapy group and the Guyuling capsule group (P<0.01). After treatment, the serum EGF (0.60 ± 0.27 μg/L vs. 0.75 ± 0.35 μg/L, 0.72 ± 0.37 μg/L, F=3.406), TGF-β1 (9.28 ± 4.19 μg/L vs. 12.36 ± 4.21 μg/L, 12.86 ± 4.69 µg/L, F=11.568), VEGF (92.58 ± 26.01 pg/ml vs. 132.69 ± 28.01 pg/ml, 127.63 ± 29.85 pg/ml, F=36.053) were significantly lower than those in the bone trauma therapy group and the Guyuling capsule group (P<0.01). Three months after operation, the cure rate was 35.2% (19/54) and the total effective rate was 81.5% (44/54) in all three groups. The cure rate and total effective rate in the combined group were better than those in the bone trauma therapy group and the Guyuling capsule group (χ²=6.373, 4.669, P=0.041, 0.031). Conclusions The treatment of traumatic fractures with bone trauma therapy instrument combined with Guyuling capsule can promote the healing of fractures, reduce the stress response caused by fractures, and improve the clinical efficacy.

Chromosomal region maintenance 1 (CRM1) is associated with an adverse prognosis in glioma. We previously reported that CRM1 inhibition suppressed glioma cell proliferation both in vitro and in vivo. In this study, we investigated the role of CRM1 in the migration and invasion of glioma cells. S109, a novel reversible selective inhibitor of CRM1, was used to treat Human glioma U87 and U251 cells. Cell migration and invasion were evaluated by wound-healing and transwell invasion assays. The results showed that S109 significantly inhibited the migration and invasion of U87 and U251 cells. However, mutation of Cys528 in CRM1 abolished the inhibitory activity of S109 in glioma cells. Furthermore, we found that S109 treatment decreased the expression level and activity of MMP2 and reduced the level of phosphorylated STAT3 but not total STAT3. Therefore, the inhibition of migration and invasion induced by S109 may be associated with the downregulation of MMP2 activity and expression, and inactivation of the STAT3 signaling pathway. These results support our previous conclusion that inhibition of CRM1 is an attractive strategy for the treatment of glioma.

Chromosomal region maintenance 1 (CRM1) is associated with an adverse prognosis in glioma. We previously reported that CRM1 inhibition suppressed glioma cell proliferation both in vitro and in vivo. In this study, we investigated the role of CRM1 in the migration and invasion of glioma cells. S109, a novel reversible selective inhibitor of CRM1, was used to treat Human glioma U87 and U251 cells. Cell migration and invasion were evaluated by wound-healing and transwell invasion assays. The results showed that S109 significantly inhibited the migration and invasion of U87 and U251 cells. However, mutation of Cys528 in CRM1 abolished the inhibitory activity of S109 in glioma cells. Furthermore, we found that S109 treatment decreased the expression level and activity of MMP2 and reduced the level of phosphorylated STAT3 but not total STAT3. Therefore, the inhibition of migration and invasion induced by S109 may be associated with the downregulation of MMP2 activity and expression, and inactivation of the STAT3 signaling pathway. These results support our previous conclusion that inhibition of CRM1 is an attractive strategy for the treatment of glioma.

A 11-year old female patient with severe thalassemia, receipt a lentivirus-based cell and gene therapy (CGT) therapy in Shenzhen Children′s Hosptial on July 27th, 2021. At the two follow-up visits after discharge, patient were continuously tested positive for HIV screening through HIV Ag/Ab Combo assay (chemiluminescence Immunoassay), and the viral load results of HIV-1 nucleic acid testing (NAT) were both>5 000 copies/ml. The patient can be diagnosed with HIV infection according to the National Guideline for Detection of HIV/AIDS(2020 Revised Edition). The thorough investigation findings and supplementary experiment results indicated that the false-positive HIV-1 NAT results was caused by cross-reactivity between the target sites detected by conventional HIV-1 NAT reagents and the lentiviral vectors fragments integrated into the genome of patient′s hematopoietic stem/progenitor cells. In conclusion, it is important for laboratories to select appropriate HIV-1 NAT testing platforms which won′t cause cross-reactivity for the testing of samples from patients who have been treated with HIV-derived vectors. It is also recommended to design and develop NAT testing platforms with multiple target regions labeled by different fluorescents for HIV NAT supplementation experiment to reduce the risk of false-positive diagnoses of HIV infection.